RNS Number: 3518 C Diurnal Group PLC 14 June 2019 NEITHER THIS ANNOUNCEMENT NOR ANY PART OF IT CONSTITUTES AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION OR...
Diurnal Group Plc (DNL.L) Announced that it has received valid acceptances and excess applications from Qualifying Shareholders in respect of a total of 2,229,578 Open Offer Shares pursuant to the terms of the Open Offer. This represents approximately 57.8% of the 3,857,617 Open Offer Shares. The Open Offer closed for acceptances on 13 June 2019. As a consequence and conditional on, amongst other things, Shareholder approval of the Resolutions at the General Meeting to be held later today and Admission, the company has raised gross proceeds of approximately £579,690 through the Open Offer and approximately £5.93 million (before expenses) in aggregate through the Placing and Open Offer
RNS Number: 1809 C Diurnal Group PLC 14 June 2019 NEITHER THIS ANNOUNCEMENT NOR ANY PART OF IT CONSTITUTES AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION OR...
RNS Number: 2236 A Diurnal Group PLC 28 May 2019 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, THE RUSSIAN FEDERATION, THE REPUBLIC OF IRELAND OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED...
Diurnal on track to submit Market Authorisation Application in Europe in Q4 2019. "Today marks the first step in the Market Authorisation Submission process in Europe for Chronocort ®. We believe that Chronocort ® represents a valuable treatment option for patients suffering from congenital adrenal hyperplasia, in a market estimated at $250 million in...
RNS Number: 9367 X Diurnal Group PLC 02 May 2019 2 May 2019. Founded in 2004, Diurnal is a UK- based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. RNS is approved by the Financial Conduct...
RNS Number: 6188 X Diurnal Group PLC 30 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6066 X Diurnal Group PLC 30 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3128 X Diurnal Group PLC 26 April 2019 26 April 2019. Director Dealings and Issue of Equity. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces the issue and allotment of 11,022 ordinary shares of £0.05 to John Goddard, Non-Executive Director of the Company, as part of a...
RNS Number: 2909 X Diurnal Group PLC 26 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Diurnal (DNL.L) 28.5p £16.66m “Alkindi® (hydrocortiso-ne granules in capsules for opening) has been granted Orphan Drug Designation in Australia by the Therapeutic Goods Administration (TGA) for the indication "replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents (from birth to <18 years old)". Orphan Drug Designation in Australia provides significant benefits, including waiver of application, evaluation and annual registration fees.” Australia and New Zealand represent significant market opportunities for Diurnal, with around 1,750 patients in these territories suffering from paediatric AI and the genetic condition congenital adrenal hyperplasia (CAH), providing an estimated total market opportunity for Alkindi®and Chronocort® of approximately $10m per annum (USD).
Diurnal Group Plc (DNL.L) Announced that Alkindi (hydrocortisone granules in capsules for opening) has been granted Orphan Drug Designation in Australia by the Therapeutic Goods Administration (TGA) for the indication "replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents (from birth to <18 years old)".
Alkindi ® granted Orphan Drug Designation in Australia. and grant of second Alkindi ® patent in Australia. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that Alkindi ® has been granted Orphan Drug Designation in Australia by the Therapeutic Goods Administration for the...
Diurnal Group Plc (DNL.L) Announced that, following a positive meeting with the European Medicines Agency (EMA) in March 2019, the company has received formal Scientific Advice from the EMA confirming the current clinical and regulatory path for Chronocort as a treatment for patients with congenital adrenal hyperplasia (CAH). Consequently, the company intends to submit a Marketing Authorisation Application (MAA) for Chronocort (modified release hydrocortisone) in Q4 2019 based upon the existing clinical data, including additional data which will be required to support Orphan Drug Status in the treatment of CAH. This positive outcome follows the submission of a regulatory package requesting Scientific Advice to the EMA for Chronocort based on detailed analysis of data from its Phase 3 study, the largest ever clinical trial programme in CAH, and the open-label safety extension study.
RNS Number: 8331 V Diurnal Group PLC 11 April 2019 11 April 2019. Positive Scientific Advice from European Medicines Agency for Chronocort ®. European Medicines Agency confirms the current clinical and regulatory path for Chronocort ®.
Diurnal Group Plc (DNL.L) Announced, in its results for the six months ended 31 December 2018, that its operating loss stood at £9.67 million, compared to £7.71 million in the preceding year. The company’s diluted loss per share was 13.4p, compared to 12.7p. Further, the company launched Alkindi in the UK as the first specifically developed and licensed replacement therapy of paediatric adrenal insufficiency and positive Scottish Medicines Consortium pricing and reimbursement decision.
RNS Number: 2508 U Diurnal Group PLC 28 March 2019 28 March 2019. Strong launches for Alkindi ® in Germany and UK with further launches planned for 2019. o Launch of Alkindi ® in the UK as the first specifically developed and licensed replacement therapy of paediatric adrenal insufficiency and positive Scottish Medicines Consortium pricing and...
First launch planned for Sweden in Q2 2019. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces a marketing and distribution agreement with Anthrop Pharmaceuticals AB, a leading, specialist pharmaceutical company based in Sweden focused on the marketing and sales of niche, high quality...
Diurnal Group plc
DNL.L
Diurnal Group plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    61.71M
Watchlist